o-(3-hydroxypropoxy)benzoic acid | 30721-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: o-(3-hydroxypropoxy)benzoic acid
• 英文别名: 3-(2-Carboxyphenoxy)propan-1-ol；2-(3-Hydroxypropoxy)benzoic acid
• CAS: 30721-20-1
• 化学式: C₁₀H₁₂O₄
• mdl: MFCD11204895
• 分子量: 196.203
• InChiKey: ZNNQGSGPVUYWOS-UHFFFAOYSA-N

物化性质

• 沸点：
  373.2±17.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  o-(3-hydroxypropoxy)benzoic acid 在 chromium(VI) oxide 、 硫酸 作用下， 以 水 、 丙酮 为溶剂， 反应 1.0h， 以60 mg的产率得到β-(2-Carboxy-phenoxy)-propionsaeure
  参考文献：
  名称：

  Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs

  摘要：

  Bryostatin 1 is in clinical trials for the treatment of cancer and alzheimer disease and is a candidate for a first in class approach to HIV/AIDS eradication. It is neither readily available nor optimally suited for clinical use. Using a funciton oriented synthesis strategy, a new class of bryostatin inspired analog was designed with a simplified salicylate-derived subunit, enabling step economical synthesis (23 total steps) of agents exhibiting bryostatin like affinity to protein kinase C (PKC).

  DOI：

  10.1021/ol502491f
• 作为产物：
  描述：

  水杨酸甲酯 在 potassium carbonate 、 potassium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 o-(3-hydroxypropoxy)benzoic acid
  参考文献：
  名称：

  Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs

  摘要：

  Bryostatin 1 is in clinical trials for the treatment of cancer and alzheimer disease and is a candidate for a first in class approach to HIV/AIDS eradication. It is neither readily available nor optimally suited for clinical use. Using a funciton oriented synthesis strategy, a new class of bryostatin inspired analog was designed with a simplified salicylate-derived subunit, enabling step economical synthesis (23 total steps) of agents exhibiting bryostatin like affinity to protein kinase C (PKC).

  DOI：

  10.1021/ol502491f

文献信息

• [EN] COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR<br/>[FR] COMPOSITIONS COMPORTANT UN INHIBITEUR DE LA PROTEASE DU VIH
  申请人：PFIZER

  公开号：WO2005056542A1

  公开（公告）日：2005-06-23

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in the manufacture of a medicament for the treatment HIV-infected mammals, such as humans.

  本发明涉及包含非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺，或其药学上可接受的盐或溶剂的制药组合物，其制备方法，其在抑制HIV蛋白酶酶的用途，以及其在制造用于治疗HIV感染哺乳动物，如人类的药物中的用途。
• Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and <i>in vivo</i> antihyperglycaemic efficacy
  作者：Lingling Yang、Feng Chen、Cheng Gao、Jiabao Chen、Junyan Li、Siyan Liu、Yuanyuan Zhang、Zhouyu Wang、Shan Qian

  DOI：10.1080/14756366.2019.1690481

  日期：2020.1.1

  In our previous work, a synthetic oleanolic acid (OA) derivative C10a with PTP1B inhibitory activity has been reported. However, C10a has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of C10a to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds 15, 28 and 34 exhibited

  在各种基础和临床研究中，蛋白酪氨酸磷酸酶1B（PTP1B）的过表达诱导胰岛素抵抗。在我们以前的工作中，已经报道了具有PTP1B抑制活性的合成齐墩果酸（OA）衍生物C10a。但是，C10a具有一些药理缺陷和细胞毒性。在本文中，基于C10a的结构使用了基于结构的药物设计方法来完善较小的三环核心。合成了一系列三环衍生物，化合物15、28和34表现出最大的PTP1B酶促抑制能力。在具有胰岛素抵抗性的人肝癌HepG2细胞中，具有中等PTP1B抑制作用和较好药物特性的化合物25可以显着增加胰岛素刺激的葡萄糖摄取，并显示出改善胰岛素抵抗的作用。而且，图25显示了在烟酰胺-链脲佐菌素诱导的T2D中改善的体内抗高血糖潜能。我们的研究表明，这些具有改善的分子结构和抗高血糖活性的三环衍生物可用于治疗T2D。
• Ortho-Directed Lithiation of ω-Phenoxy Alcohols
  作者：Constantinos S. Salteris、Ioannis D. Kostas、Maria Micha-Screttas、George A. Heropoulos、Constantinos G. Screttas、Aris Terzis

  DOI：10.1021/jo990443p

  日期：1999.7.1

  resulting lithiated compounds with carbon dioxide (n = 2-7), benzaldehyde (n = 2-6), benzophenone (n = 2, 3), dimethylformamide (n = 2), ethyl formate (n = 2), and chlorodiphenylphosphine (n = 3) afforded the corresponding ortho-substituted hydroxyalkoxybenzenes in yields ranging from 45 to 83%. The synthesis is also reported of five new bis[o-(omega-hydroxyalkoxy)phenyl]mercury compounds (n = 2-6), four

  ω-苯氧基醇PhO（CH（2））（n）（）OH（n = 2-7）已在四氢呋喃/甲基环己烷溶剂中用2当量的正丁基锂金属化。所得锂化化合物与二氧化碳（n = 2-7），苯甲醛（n = 2-6），二苯甲酮（n = 2、3），二甲基甲酰胺（n = 2），甲酸乙酯（n = 2），氯二苯膦（n = 3）得到相应的邻位取代的羟基烷氧基苯，产率为45％至83％。还报道了五种新的双[邻-（ω-羟基烷氧基）苯基]汞化合物（n = 2-6）的合成，已确定了其中的四种晶体结构。
• Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
  申请人：XenoPort, Inc.

  公开号：US20140056973A1

  公开（公告）日：2014-02-27

  Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

  口服剂型和颗粒制剂中含有高含量的甲基氢富马酸前药。
• Pharmaceutical compositions of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20010053778A1

  公开（公告）日：2001-12-20

  Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.

  药物组合物包括一种糖原磷酸化酶抑制剂和至少一种浓度增强聚合物。该组合物可以是糖原磷酸化酶抑制剂和浓度增强聚合物的简单物理混合物，也可以是糖原磷酸化酶抑制剂和聚合物的分散体。